

Agenda: February 14, 2001

Psychopharmacological Drugs Advisory Committee

Holiday Inn, Gaithersburg, Maryland

NDA 21-253: Zyprexa® (olanzapine IM, Eli Lilly, Inc.)

8:00 Call to Order, Introductions

Carol Tamminga, M.D., Chair, PDAC

Conflict of Interest Statement

Sandra Titus, Ph.D., Executive Secretary, PDAC

Welcome

Russell Katz, M.D., Director, Neuropharmacological Drug Products

8:15 Overview of Issues

Thomas Laughren, M.D., Team Leader, Psychiatric Drug Products Group

8:30 Committee Discussion on General Issues of Research on Agitated Patients

10:15 Break

10:30 Lilly Presentations

The Agitated Patient

John Kane, M.D., Chairman, Department of Psychiatry, Hillside Hospital; Professor of Psychiatry, Neurology and Neuroscience, The Albert Einstein College of Medicine

Clinical Development of IM Olanzapine

Alan Breier, M.D., Leader, Zyprexa Product Team, Lilly; Professor of Psychiatry, Indiana University

12:00 Lunch

1:00 Open Public Hearing

2:00 Committee Discussion Continues

4:30 Time of Adjournment may vary